Our Custom Soultions for Rare Diseases

Competitive Intelligence

Staying abreast of the rapid changes in the healthcare environment is paramount. Through a combination of robust data, and expert opinion and analysis, we provide real-time actionable insights to our partners and enable them to make informed decisions.

Some of our key services include:

  • Regulatory Assessment
  • Opinion Analysis
  • Congress Intelligence
  • Strategy Assessment
  • News Assessment

Our competitive intelligence consulting services provide research-based solutions to help you gain a competitive advantage. Our strategy considers the perspectives of customers, suppliers, business competitors, and others. We gather market data from all corners of the industry and transform it into useful information. Our competitive intelligence team, composed of analysts, senior analysts, managers, and key opinion leaders (KOLs), provides our partners with the most up-to-date and accurate intelligence.

Featured Newsletter
Featured Newsletter

PD-1/PD-L1 inhibitors

Cancer immunotherapy known to reactivate weakened immune cells of cancer patients, has yielded great success in recent years. Promising antitumor effects have been demonstrated in several solid and hematological malignancies by introducing PD-1/PDL-1 blockade therapy. There is a growing concern about whether they are comparable as the use of PD-1/PDL-1 inhibitors is increasing in number for the clinical treatment of cancer.

Related Insight

Myotonic Dystrophy: In Search of Effective Weaponry to Kick Out Toxic RNAs Weakening Muscles
Article

Myotonic Dystrophy: In Search of Effective Weaponry to Kick Out Toxic RNAs Weakening Muscles

Read More
Gene Therapy: The Next Milestone and Ultimate Option in a Fight Against Complex Diseases
Article

Gene Therapy: The Next Milestone and Ultimate Option in a Fight Against Complex Diseases

Read More
How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle The Treatment Landscape?
Article

How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle The Treatment Landscape?

Read More
Roche’s HEMLIBRA: A Game Changer Drug for Hemophilia A Treatment and Hope for Patients
Article

Roche’s HEMLIBRA: A Game Changer Drug for Hemophilia A Treatment and Hope for Patients

Read More
Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar AATD Treatment Market
Article

Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar AATD Treatment Market

Read More
What Factors are Shaping the Trends in the Cutaneous T-cell Lymphoma (CTCL) Treatment Market?
Article

What Factors are Shaping the Trends in the Cutaneous T-cell Lymphoma (CTCL) Treatment Market?

Read More

Want top-notch orphan drug consulting? Get in touch with our team

Reports

Myelofibrosi
Progressive-Multifocal
Whim-SyndromeMultifocal
Wilson-Disease
Atypical-Hemolytic
AL-Amyloidosisand
Adrenal-Crisis
Congenital-Adrenal-Hyperplasia
Autosomal-Dominant
Focal-Segmental
Dystrophic-Epidermolysis
Fabry-Disease
Developmentals
Cystic-Fibrosis
Featured Newsletter

Case Studies

Featured Newsletter

In-Licensing Opportunity

A large client based in the USA wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products.

Featured Newsletter

Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs.

Featured Newsletter

Due Diligence

A medium pharmaceutical client with capabilities in novel formulations was involved in a deal with a manufacturing company for commercial-scale manufacturing of the client’s therapies.

Get Expert Consultation Now!

To succeed in the rare disease market, research companies must have a distinct business model and a carefully tailored set of capabilities in R&D, market access, and commercial aspects. We provide the best strategy and operating model required to succeed in this winner-take-all market.

  • More than 200 orphan disease reports are in the repository to provide a better understanding of the rare disease market landscape.
  • Epidemiological assessment of unexplored rare diseases and their forecast patterns.
  • Understand the treatment paradigms and patient journeys across different geographies
  • Stay ahead in competition with the conclusions derived from the perspectives of indication-based KOL panels for different countries
  • Best-in-class strategies for rare disease assets in different clinical trial phases.
  • Strategizing Rare disease development business model
  • Analyze the needs of the patient and caregiver in a disease state to create a patient-centric model.
  • Expert opinions from key industry leaders to validate assumptions and rationale for better market assessment.